Stanford researchers have developed potent protein Kinase inhibitors for inhibition of pathological activity of protein kinases involved in cell death, inflammation and cancer.
Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD.